What's new

Human medicines European public assessment report (EPAR): Ranivisio, ranibizumab, Date of authorisation: 25/08/2022, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Ranivisio, ranibizumab, Date of authorisation: 25/08/2022, Revision: 5, Status: Authorised

May 27, 2025 - 10:55
 0
Human medicines European public assessment report (EPAR): Ranivisio, ranibizumab, Date of authorisation: 25/08/2022, Revision: 5, Status: Authorised
Human medicines European public assessment report (EPAR): Ranivisio, ranibizumab, Date of authorisation: 25/08/2022, Revision: 5, Status: Authorised
Read More

Tags:

Previous Article

Navigating the evolving landscape of fill/finish: Challenges and what’s ahead

Next Article

Killing drones softly

Related Posts

Human medicines European public assessment report (EPAR): Uzpruvo, ustekinumab, Date of authorisation: 05/01/2024, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR...

May 16, 2025  0

Minutes of the HMPC meeting 17-19 March 2025

May 12, 2025  0

Human medicines European public assessment report (EPAR): Isentress, raltegravir, Date of authorisation: 19/12/2007, Revision: 44, Status: Authorised

Human medicines European public assessment report (EPAR...

May 14, 2025  0